Literature DB >> 6418829

Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum.

J Levy, A L Smith, M A Kenny, B Ramsey, F D Schoenknecht.   

Abstract

Two mechanisms of potential biologic antagonism of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis were studied: reduction of activity by ions and antibiotic binding. Antagonism by ions was assessed by examination of the activity of gentamicin against Pseudomonas aeruginosa in dialysates of serum or sputum in ion-depleted broth. The ionic content of the dialysates increased and reflected differences in the ion content of serum and sputum. Gentamicin had significantly less activity against P aeruginosa in sputum or serum dialysates than in ion-depleted broth alone. When gentamicin was mixed with serum or sputum before dialysis, the level of antipseudomonas activity of the sputum dialysates was significantly lower than that of the serum dialysate; this finding was correlated with greater binding by sputum. Thus, both binding and antagonism by ions evidently reduce the level of bioactivity of gentamicin in serum and in sputum. Purulent sputum, whether from children with cystic fibrosis or adults which bronchiectasis, is more inhibitory than serum; the greater degree of binding, rather than differences in the composition or quantity of cations, explains this difference.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418829     DOI: 10.1093/infdis/148.6.1069

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.

Authors:  D M Rothstein; P Spacciapoli; L T Tran; T Xu; F D Roberts; M Dalla Serra; D K Buxton; F G Oppenheim; P Friden
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Is prolonged rotavirus infection a common cause of protracted diarrhoea?

Authors:  M Sood; I W Booth
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

3.  Evidence for using nebulised antibiotics in cystic fibrosis.

Authors:  S P Conway
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

4.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

Review 5.  Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin.

Authors:  Jennifer Ruddy; Julia Emerson; Richard Moss; Alan Genatossio; Sharon McNamara; Jane L Burns; Gail Anderson; Margaret Rosenfeld
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-05-23       Impact factor: 2.849

7.  Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.

Authors:  N N Sanders; H Franckx; K De Boeck; J Haustraete; S C De Smedt; J Demeester
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

8.  Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis.

Authors:  J L Gaillard; P Cahen; C Delacourt; C Silly; M Le Bourgeois; C Coustère; J de Blic; G Lenoir; P Scheinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

9.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.